At 17.4% CAGR, the Asia Pacific Breath Analyzer Market is Projected to be Worth US$ 834.77 Million by 2030, says Business Market Insights

According to Business Market Insights research, the Asia Pacific breath analyzer market was valued at US$ 230.62 million in 2022 and is expected to reach US$ 834.77 million by 2030, registering a CAGR of 17.4% from 2022 to 2030. Favorable and supportive regulations for adoption of breath analyzers and advanced technologies implementation for breath analyzers by key market players are the critical factors attributed to the Asia Pacific breath analyzer market expansion.

Market players launch innovative products such as "Contact-Free Breath Analyzer." In May 2023, Cannabix Technologies Inc., a manufacturer of breath testing devices, announced the development of contactless alcohol breathalyzer (CAB) technology in the workplace and in-cabin vehicles. The company ran a pilot testing of its workplace CAB in Montana-based Friedel LLC in March 2023. Since then, the device has been performing well, with over 300 breath samples taken till today. The company's CAB product has received strong interest from the US and Australia for the development and commercialization of a CAB product targeting small to medium-sized enterprises (SMEs). The CAB product proves especially effective with pre-alcohol testing before and during work hours of an employee. Furthermore, the device can be utilized in bars, restaurants, hotels, and organizations. Additionally, in 2023, the Queensland's government stated that it is considering the random breath testing (RBT) initiative in Queensland to be extended to cover scooter and bicycle riders. Thus, favorable regulations for adoption of breath analyzers are expected to provide lucrative opportunities for the breath analyzer manufacturers in the long run.

On the contrary, false results by breath analyzers hampers the Asia Pacific breath analyzer market.

Based on technology, the Asia Pacific breath analyzer market is segmented into fuel cell technology, infrared spectroscopy, semiconductor sensor, and others. The fuel cell technology segment held 58.3% share of Asia Pacific breath analyzer market in 2022, amassing US$ 134.52 million. It is projected to garner US$ 512.66 million by 2030 to expand at 18.2% CAGR during 2022-2030.

In terms of application, the Asia Pacific breath analyzer market is categorized into alcohol detection, medical applications, and drug abuse detection. The medical applications segment held 50.5% share of Asia Pacific breath analyzer market in 2022, amassing US$ 116.52 million. It is projected to garner US$ 438.37 million by 2030 to expand at 18.0% CAGR during 2022-2030.

Based on end user, the Asia Pacific breath analyzer market is categorized into hospitals and diagnostic centers, law enforcement agencies, and others. The hospitals and diagnostic centers segment held 46.5% share of Asia Pacific breath analyzer market in 2022, amassing US$ 107.24 million. It is projected to garner US$ 380.83 million by 2030 to expand at 17.2% CAGR during 2022-2030.

By country, the Asia Pacific breath analyzer market has been categorized into China, Japan, India, South Korea, Australia, and the Rest Asia Pacific. Our regional analysis states that China captured 26.6% share of Asia Pacific breath analyzer market in 2022. It was assessed at US$ 61.37 million in 2022 and is likely to hit US$ 248.51 million by 2030, exhibiting a CAGR of 19.1% during 2022-2030.

Key players operating in the Asia Pacific breath analyzer market are Thermo Fisher Scientific Inc, Alcolizer Pty Ltd, Dragerwerk AG & Co KGaA, Abbott Laboratories, Honeywell International Inc, KHN Solutions LLC, Bedfont Scientific Ltd, and Intoximeters Inc, among others.

• In Apr-2023, Drager launched the new Alcotest 6000, an improvement from the Alcotest 5820. The Alcotest 6000 identifies alcohol-impaired individuals, helping lawmakers and employers make effective decisions before the subject becomes a liability.
  
  
• In Apr-2022, Inspect Systems' InspectIR COVID-19 Breathalyzer gets FDA authorization for rapid detection of five Volatile Organic Compounds (VOCs) associated with SARS-CoV-2 infection.
  
  
• In Apr-2021, the E-Nose device developed at NASA's Ames Research Center in California's Silicon Valley using patented nanosensors and nanosensor array technologies is a smartphone-based device derived from technology used to help monitor air quality inside spacecraft, but NASA advanced it to detect COVID-19 by "sniffing" a person's breath.
  
  
  
  
  Contact Us
  Phone: +16467917070
  Email Id: sales@businessmarketinsights.com